The FDA has accepted a supplemental biologics license application and granted priority review to durvalumab in combination with standard gemcitabine and cisplatin for the treatment of patients with locally advanced or metastatic biliary tract cancer.
Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.
Pembrolizumab with or without chemotherapy resulted in a numerically longer overall survival benefit vs cetuximab plus chemotherapy in patients with head and neck squamous cell carcinoma and a PD-L1 combined positive score (CPS) between 1 and 19, but did not improve survival in the subset with a PD-L1 CPS of less than 1.
The addition of apalutamide to androgen deprivation therapy was not found to significantly reduce health-related quality of life or increase patient-reported adverse effect burden in patients with metastatic castration-sensitive prostate cancer enrolled to the phased 3 TITAN trial.
The European Commission has approved the use of cabozantinib for use as a single agent in adult patients with locally advanced or metastatic differentiated thyroid carcinoma who are refractory or not eligible to receive radioactive iodine and who have progressed during or following previous systemic treatment.
Thomas Martin, MD, discusses updates from the CARTITUDE-1 trial, as well as the future of CARs and bispecific T cell engagers in multiple myeloma.
Heather McArthur, MD, MPH, discusses key treatment developments in early-stage and metastatic HER2-positive breast cancer and triple-negative breast cancer, plus ongoing research at UT Southwestern Harold C. Simmons Comprehensive Cancer Center.
Press Release
Mount Sinai researchers conducting clinical trials of a drug targeting a cancer gene found that it increased metastatic cancer patients’ survival and was able to work within the brain.
The FDA has accepted a supplemental new drug application and granted priority review to darolutamide plus docetaxel in patients with metastatic hormone-sensitive prostate cancer.
Lori A. Leslie, MD, reviews how the approval of axicabtagene ciloleucel may impact or enhance current practice patterns for adult patients with large B-cell lymphoma.
Anthony Mato, MD, MSCE, discusses current data surrounding BTK inhibitors in chronic lymphocytic leukemia, the benefits of targeted therapies in this population, ways to begin addressing unmet needs, and the importance of improved clinical trial designs for varying patient populations.
The FDA is seeking the approval of toripalimab plus gemcitabine and cisplatin in the frontline treatment of patients with advanced recurrent or metastatic nasopharyngeal carcinoma and for use as a monotherapy in the second-line and later treatment of those with recurrent or metastatic disease.
Although it is not considered to be a standard of care for patients with indolent non-Hodgkin lymphoma, very low dose radiation therapy was found to have efficacy in the palliative setting and to allow for retreatment to the same field when needed.
The time-limited combination of ublituximab and umbralisib plus ibrutinib resulted in an undetectable minimal residual disease rate of 77% in patients with chronic lymphocytic leukemia, according to findings from a phase 2 trial (NCT04016805)
Andrew J. Armstrong, MD, discusses the updated results and the clinical implications of the final survival analysis of the ARCHES trial, which he coauthored.
The FDA has issued a complete response letter to the new drug application seeking the approval of surufatinib for the treatment of patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Press Release
Dana-Farber Cancer Institute and the Lifespan Cancer Institute have agreed to renew their strategic alliance to advance cancer treatment and research. Dana-Farber and the Lifespan Cancer Institute signed an initial agreement in 2017.
Maurie Markman, MD, discusses the need for oncologists to improve communication with the public and patients.
Reshma Mahtani, DO, discusses the use of antibody-drug conjugates, tyrosine kinase inhibitors, CDK4/6 inhibitors, and PARP inhibitors across HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.
Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.
The combination of ceralasertib and acalabrutinib showed preliminary clinical activity with acceptable tolerability in patients with high-risk, relapsed/refractory chronic lymphocytic leukemia.
The National Comprehensive Cancer Network has released new guidelines for ampullary adenocarcinoma, a disease accounting for just 0.2% of all gastrointestinal malignancies.
Adjuvant capecitabine continues to demonstrate an improvement in overall survival compared with observation following curative-intent resection in patients with biliary tract cancer.
Press Release
Renowned robotic urologic oncology surgeon Dipen J. Parekh, MD, was the first in the nation to test a new preoperative surgical rehearsal technology recently approved by the FDA for all genitourinary conditions.
The European Commission has granted an approval to the combination of pembrolizumab and chemotherapy, with or without bevacizumab, for the treatment of adult patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher.
The European Commission has granted an approval to pembrolizumab for the treatment of patients with select microsatellite instability–high or deficient mismatch repair solid tumors.
The National Comprehensive Cancer Network is advising individuals who are immunocompromised, including those with cancer, to receive a fifth COVID-19 vaccination.
The administration of a third dose of a SARS-CoV-2 mRNA vaccine yielded seroconversion responses in patients treated with hematopoietic cell transplantation or cellular therapy following initial failure of seroconversion after the first 2 vaccine doses.
As cancer care continues to shift away from a fee-for-service model to a value-based care model, clinicians and institutions will need to be adaptable and innovative to build effective community oncology practices of the future.
New data ranging from up-front approaches with targeted therapy to maintenance therapy, as well as emerging findings with novel agents continue to push the paradigm forward in acute myeloid leukemia and higher-risk myelodysplastic syndromes.
